ArticleAsian Pacific journal of cancer prevention : APJCP2025
Anticancer Activity of Secondary Metabolites Extracted from Endophytic Fungus in Pongamia pinnata Barks.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveEndophytic fungi, particularly Trichoderma species, offer significant potential for the isolation of novel natural bioactive compounds with diverse applications in agriculture, medicine, and the food industry. These compounds are reliable, cost-effective, and environmentally safe. In this study, we evaluated the efficacy of secondary metabolites extracted from Trichoderma species against the JURKAT cell line.
methodsTrichoderma species were utilized in the fermentation process to produce secondary metabolites, which were subsequently evaluated for anticancer activity against the JURKAT cell line using MTT, LDH, apoptotic assays, and gene expression studies.
resultsThe study demonstrated that the ethyl acetate extract of Trichoderma secondary metabolites significantly reduced cell viability and increased LDH leakage, indicating potent anti-proliferative activity against the JURKAT cell line. Cytotoxicity ranged from 35.12 ± 0.45% to 58.56 ± 1.16% at varying concentrations. The extract significantly increased the percentage of cells arrested in the G2/M phase from 8.48% to 21.11%, while reducing cell viability from 94.3% to 54.35% and elevating early apoptotic cells from 1.12% to 21.34%. Real-time PCR analysis revealed a dose-dependent upregulation of the caspase 3 gene, whereas caspase 8 was downregulated.
conclusionThe secondary metabolites extracted from Trichoderma show promise for further early-stage clinical trials, including pharmacodynamic studies and in vivo investigations using animal models. In conclusion, these extracts exhibit significant anti-carcinogenic potential and could serve as a therapeutic agent for treating leukaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.